Peptides as drug delivery vehicles across biological barriers

被引：74

作者：

Ghosh D. ^{[1
]}

Peng X. ^{[1
]}

Leal J. ^{[1
]}

Mohanty R.P. ^{[1
]}

机构：

[1] Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, 78712, TX

来源：

Journal of Pharmaceutical Investigation | 2018年 / 48卷 / 1期

关键词：

Blood–brain barrier; Carrier; Drug delivery; GI; Peptides; Tumor;

D O I：

10.1007/s40005-017-0374-0

中图分类号：

学科分类号：

摘要：

Peptides are small biological molecules that are attractive in drug delivery and materials engineering for applications including therapeutics, molecular building blocks and cell-targeting ligands. Peptides are small but can possess complexity and functionality as larger proteins. Due to their intrinsic properties, peptides are able to overcome the physiological and transport barriers presented by diseases. In this review, we discuss the progress of identifying and using peptides to shuttle across biological barriers and facilitate transport of drugs and drug delivery systems for improved therapy. Here, the focus of this review is on rationally designed, phage display peptides, and even endogenous peptides as carriers to penetrate biological barriers, specifically the blood–brain barrier (BBB), the gastrointestinal tract (GI), and the solid tumor microenvironment (T). We will discuss recent advances of peptides as drug carriers in these biological environments. From these findings, challenges and potential opportunities to iterate and improve peptide-based approaches will be discussed to translate their promise towards the clinic to deliver drugs for therapeutic efficacy. © 2017, The Korean Society of Pharmaceutical Sciences and Technology.

引用

页码：89 / 111

页数：22

共 185 条

[1]

Ac't hoen P.A.C., Jirka S.M.G., Ten Broeke B.R., Et al., Phage display screening without repetitious selection rounds, Anal Biochem, 421, pp. 622-631, (2012)

[2]

Agarwal V., Current status of the oral delivery of insulin, Pharm Technol, 25, pp. 76-90, (2001)

[3]

Agemy L., Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma, Proc Nat Acad Sci, 108, pp. 17450-17455, (2011)

[4]

Aguirre T.A.S., Teijeiro-Osorio D., Rosa M., Et al., Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials, Adv Drug Deliv Rev, 106, pp. 223-241, (2016)

[5]

Akerman M.E., Chan W.C.W., Laakkonen P., Et al., Nanocrystal targeting in vivo, Proc Natl Acad Sci USA, 99, pp. 12617-12621, (2002)

[6]

Alberici L., Roth L., Sugahara K.N., Et al., De novo design of a tumor-penetrating peptide, Cancer Res, 73, pp. 804-812, (2013)

[7]

Alitalo K., Carmeliet P., Molecular mechanisms of lymphangiogenesis in health and disease, Cancer Cell, 1, pp. 219-227, (2002)

[8]

Arap W., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 279, pp. 377-380, (1998)

[9]

Bagri A., Tessier-Lavigne M., Watts R.J., Neuropilins in tumor biology, Clin Cancer Res, 15, pp. 1860-1864, (2009)

[10]

Bastian S.E.P., Walton P.E., Ballard F.J., Belford D.A., Transport of IGF-I across epithelial cell monolayers, J Endocrinol, 162, pp. 361-369, (1999)

← 1 2 3 4 5 6 7 8 9 10 →